Myo-EXERTBC: A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 21
- 试验地点
- 1
- 主要终点
- Change in Myokine Production After First Exercise Session
研究概览
简要总结
In this pilot study, the investigators will assess the changes in myokine production based on several different exercise regimens.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 89 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Age 20-89 years
- •Women prescribed exercise as a SOC
- •Women with a biopsy proven diagnosis of ductal carcinoma in situ (DCIS) or invasive carcinoma of the breast
- •Women must have undergone treatment for breast cancer, including one or more of the following: surgery, radiation therapy, chemotherapy, immunotherapy, or hormonal therapy. Women undergoing active chemotherapy are not allowed on study. Immunotherapy or targeted agent usage is allowed.
- •Women with > 3 months of resistance training experience under expert guidance at the Allegheny Health Network Exercise Oncology Center
排除标准
- •Any current treatment with cytotoxic chemotherapy for breast cancer
- •Inability to safely engage in group sessions of resistance training as deemed by study PI
- •Severe arthritic, joint, cardiovascular, or musculoskeletal condition deemed by PI to be unsafe to engage in resistance training
- •Pregnant women
研究组 & 干预措施
Strength Regimen Group
干预措施: Strength Resistance Training (Behavioral)
Hypertrophy Regimen Group
干预措施: Hypertrophy Resistance Training (Behavioral)
Conditioning Regimen Group
干预措施: Conditioning Resistance Training (Behavioral)
结局指标
主要结局
Change in Myokine Production After First Exercise Session
时间窗: Immediately before and immediately after the first exercise session.
Quantification of a panel of 15 myokines (IL-5, IL-1ra, LIF, Irisin, SPARC, Decorin, Oncostatin M, Myostatin, Follistatin, Apelin, Fibroblast Growth Factor 21 (FGF21), Cathepsin-B, IL-15, METRNL, Myonectin) in both serum and tear samples. The change from pre-exercise to post-exercise levels will be determined.
Change in Myokine Production After Final Exercise Session of Each Week
时间窗: Immediately before and immediately after the final exercise session of weeks 1, 2, 3, and 4.
Quantification of a panel of 15 myokines (IL-5, IL-1ra, LIF, Irisin, SPARC, Decorin, Oncostatin M, Myostatin, Follistatin, Apelin, Fibroblast Growth Factor 21 (FGF21), Cathepsin-B, IL-15, METRNL, Myonectin) in both serum and tear samples for each group. The change from pre-exercise to post-exercise levels at the end of each week will be determined.
Change in Myokine Production After Final Exercise Session of the Month (End of Study)
时间窗: Immediately before and immediately after the final exercise session of week 4 (end of the 4-week exercise regimen).
Quantification of a panel of 15 myokines (IL-5, IL-1ra, LIF, Irisin, SPARC, Decorin, Oncostatin M, Myostatin, Follistatin, Apelin, Fibroblast Growth Factor 21 (FGF21), Cathepsin-B, IL-15, METRNL, Myonectin) in both serum and tear samples for each group. The change from pre-exercise to post-exercise levels at the culmination of the 4-week exercise period will be determined.
次要结局
未报告次要终点
研究者
Colin Champ, MD
Principal Investigator
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)